position 3. Among the 16 MTMs described, the MTMR3, 6, 7 and 14 (JUMPY) proteins are thought to be involved in the inhibition of autophagosome formation and therefore of autophagy (I. Vergne FEBS Lett 2010, N. Taguchi-Atarashi et al . Traffic 2010).

Role of Vps34/PIK3C3 in autophagy

The PI3P formed by Vps34/PIK3C3 is a key secondary messenger in autophagosome formation by the recruitment of proteins such as WIPI, DFCP1 and Alfy (S. Tooze et al, Nat Cell Biol 2010). The autophagosomes formed will then fuse with lysosomes, making it possible to degrade constituents of the cytoplasm (organelles, long-lived proteins, etc.) (Z Yang et al. Nat Cell Biol 2010).

Autophagy is a mechanism of cell survival which enables the cell to survive in a situation of stress, for instance faced with a metabolic stress. In the case of cancer, autophagy is implicated in the resistance of tumour cells faced with environmental stresses, such as: hypoxia, oxidative stresses, nutrient deficiency, but also faced with therapeutic stresses: treatments with anticancer agents, ionizing radiation. Furthermore, this signalling pathway is a major factor of resistance to chemotherapy, to radiotherapy and to targeted therapies such as inhibitors of EGFR, HER2 or Bcr-Abl for example (QW. Fan et al., Since signaling 2010, A. Gupta et al. PNAS 2010, X Li et al. Cancer Res 2010, A Vazquez-Martin et al. PLos One 2009, Z. Wu et al. Genes Cancer 2010).

Role of Vps34/PIK3C3 in endocytosis

At the endosome level, PI3P makes it possible to recruit molecules bearing FYVE (Fab1 YOTB, Vac1 and EEA1 ) or PX (Phox-homology) motifs, such as EEA1 , HRS or SNXs, thus resulting in the fusion of endocytic vesicles. The Vps34/PIK3C3 protein has been described as being involved in the endosomal trafficking of certain transmembrane receptors such as receptor tyrosine kinases (EGF receptor, PDGF receptor) or the transferrin receptor, for example (B. Vanhaesebroeck et al . Nat Rev Mol Cell Biol 2010). Finally, Vps34, via the regulation of endosomes, has been shown to participate in the cytokinesis phenomenon during cell division (AP Sagona et al. Nat Cell Biol 2010).

Role of Vps34/PIK3C3 in phagocytosis

PI3P is also generated at the membranes of phagosomes. The role of the Vps34/PIK3C3 protein does not appear to be involved in phagosome membrane initiation, but in phagosome maturation. Finally, the PI3P formed by the Vps34/PIK3C3 protein is thought to be involved in the activation of NADPH oxidase at the phagosome level (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010).

Kinase-inhibiting morpholinopyrimidinone derivatives are known to those skilled in the art.

Application WO2008/148074 describes products which have an mTOR-inhibiting activity. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Application WO2008/064244 describes the application of the ΡΙ3Κβ-inhibiting products TGX-221 and TGX-155 which are of use in the treatment of cancer, and in particular in breast cancer. These products are pyrido[1 ,2- a]pyrimidin-4-ones previously described in applications WO2004/016607 and WO2001 /053266, which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Applications WO2006/109081 , WO2006/109084 and WO2006/126010 describe DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Application WO2003/024949 describes DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1 ,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

The subject of the present invention is the products of formula (I):

in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e):

a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

b) R1 is a -(CH2)m-Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy radical;

c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyi radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyi, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

d) R1 is an -SO2-Rb radical;

e) R1 is a -CO-Re radical;

Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical;

Rc is a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyi, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and -NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and -NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyi radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R1 1 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals:

and the isomer of configuration R,R

the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals;

all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO2alk radical, where appropriate on a nitrogen atom;

all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms,

it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom;

it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

Thus, in the products of formula (I) as defined above, R2 and R3, which may be identical or different, are such that R2 is a hydrogen atom or an alkyl radical optionally substituted with one or more fluorine atoms and R3 is an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF3; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical as defined above.

A subject of the present invention is the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals: .

the radicals p, q, R1 , R2, R3 and R4 having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0;

the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0;

the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

In the products of formula (I) according to the present invention,

- the term alkyl (or alk) radical denotes linear and branched radicals containing from 1 to 10 carbon atoms, such as: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl, and also the linear or branched positional isomers thereof: preference is given to the alkyl radicals containing from 1 to 6 carbon atoms and more particularly the alkyl radicals containing from 1 to 4 carbon atoms of the list above;

- the term alkenyl radical denotes linear and branched radicals containing from 2 to 10 carbon atoms, chosen from the alkyl radicals defined above containing one or more double bonds, such as allyl, but-3-enyl or pent-4-enyl, and also the linear or branched positional isomers thereof: preference is given to the allyl and but-3-enyl radicals;

-the term alkoxy radical denotes the linear and branched radicals, containing from 1 to 10 carbon atoms, methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy or hexoxy, and also the linear or branched positional isomers thereof: preference is given to the alkoxy radicals containing from 1 to 4 carbon atoms of the list above;

-the term alkythio or -S(O)x alkyl denotes the linear, and where appropriate branched, radicals in which the alkyl residue has the definition indicated above for the alkyl radical; -S(O)x alkyl thus in particular represents -S(O)x methyl, -S(O)x ethyl, -S(O)x propyl, -S(O)x isopropyl, linear, secondary or tertiary -S(O)x butyl, -S(O)x pentyl or -S(O)x hexyl and also the

linear or branched positional isomers thereof: preference is given to the -S(O)x alkyl radicals containing from 1 to 4 carbon atoms of the list above;

-the term halogen atom denotes chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom;

-the term cycloalkyl radical denotes a saturated carbocyclic radical containing from 3 to 10 carbon atoms, and thus denotes in particular the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and quite particularly the cyclopropyl, cyclopentyl and cyclohexyl radicals;

- in the -O-cycloalkyl radical, the cycloalkyl radical is as defined above;

-the term heterocycloalkyl radical thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 ring members, interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms: mention may, for example, be made of morpholinyl, thiomorpholinyl, homomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydropyran, oxodihydropyridazinyl, or else oxetanyl radicals, all these radicals being optionally substituted; mention may in particular be made of morpholinyl, thiomorpholinyl, homomorpholinyl, piperazinyl, piperidyl, homopiperazinyl or else pyrrolidinyl radicals;

-the terms aryl and heteroaryl denote monocyclic or bicyclic, respectively, carbocyclic and heterocyclic, unsaturated or partially unsaturated radicals containing at most 12 ring members, which can optionally contain a -C(O) ring member, the heterocyclic radicals containing one or more heteroatoms, which may be identical or different, chosen from O, N or S with N, where appropriate, optionally substituted;

-the term aryl radical thus denotes monocyclic or bicyclic radicals containing from 6 to 12 ring members, such as, for example, phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly phenyl and

naphthyl radicals and even more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a -C(O) ring member is, for example, the tetralone radical;

- the term heteroaryl radical thus denotes monocyclic or bicyclic radicals containing from 5 to 12 ring members: monocyclic heteroaryl radicals such as, for example, the radicals: thienyl such as 2-thienyl and 3-thienyl, furyl such as 2-furyl or 3-furyl, pyrannyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, triazolyl, thiatriazolyl, oxadiazolyl, isoxazolyl such as 3- or 4-isoxazolyl, furazanyl, free or salified tetrazolyl, all these radicals being optionally substituted, among which are more particularly the radicals: thienyl such as 2-thienyl and 3-thienyl, thiazolyl, furyl such as 2-furyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these radicals being optionally substituted; bicyclic heteroaryl radicals such as, for example, the radicals: benzothienyl (benzothiophene) such as 3-benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, quinolone, tetralone, adamentyl, benzofuryl, isobenzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, imidazopyridine, benzoxazinyl, benzoxazolyl, thionaphthyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, purinyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, dihydropyrrolopyridyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl or oxodihydropyridinopyrazolyl, all these radicals being optionally substituted.

As examples of heteroaryl or bicyclic radicals, mention may be made more particularly of pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl, benzothiazolyl or benzimidazolyl radicals optionally substituted with one or more substituents, which may be identical or different, as indicated above.

claim:

1 ) Products of formula (I):

in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e):

a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

b) R1 is a -(CH2)m-Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy radical;

c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyl radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyl, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

d) R1 is an -SO2-Rb radical;

e) R1 is a -CO-Re radical;

Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical;

Rc is a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyi, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and -NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and -NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyi radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R1 1 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals:

and the isomer of configuration R,R

the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals;

all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO2alk radical, where appropriate on a nitrogen atom;

all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms,

it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom;

it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

2) Products of formula (I) as defined in Claim 1 , in which the morpholine residue is chosen from the following radicals:

,R

the radicals p, q, R1 , R2, R3 and R4 having the meanings indicated in Claim 1 ,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

3) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0;

the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1 ,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

4) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0;

the radicals R1 , R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1 ,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

5) Products of formula (I) as defined in Claim 1 or 2, in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyi, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; a -(CH2)m-Ra radical; an -SO2-phenyl radical optionally substituted with an alkyl radical; a -CO-alkyl radical; an alkylene radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms;

m is the integer 1 or 2;

Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO2Rd; -CONRxRy; a -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO-piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyi, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyi, heterocycloalkyi, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, heterocyloalkyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyi radical;

NRxRy are such that Rx and Ry, which may be identical or different, are a hydrogen atom or an alkyl, alkoxy or phenyl radical or else together form a piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1 ,2}oxazinane radical;

R2 and R3 are such that:

either R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF3;

or R2 is a methyl radical and R3 is the trifluoromethyl radical CF3;

or R2 and R3 are both a methyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is chosen from the following radicals:

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

6) Products of formula (I) as defined in any one of the other claims, corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylmethyl-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1 ,2-a]pynmidin-1 -yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl- [1 ,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-nnethylnnorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lmidazo[1 ,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-((R)-3-methylnnorpholin-4-yl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-2-((R)-3-methylnnorpholin-4-yl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6-tnfluoromethylpyndin-3-yl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)ethyl]-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]oxadiazol-2-ylmethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-lsoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-lsopropoxypyridin-4-yl)-2-((R)-3-methylnnorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-lsopropoxypyridin-3-yl)-2-((R)-3-methylnnorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1 ,3,4]thiadiazol-2-ylmethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1 ,2,3]thiadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pynmidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8-tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1 -(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl-[1 ,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (R)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

- single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ^ a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Chloropyndin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-tnfluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(1 -Difluoromethyl-1 H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3-ylethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-5-ylmethyl-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -oxazol-4-ylmethyl-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2-oxobutyl)-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-0X0-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-1 -(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-tnfluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoronnethyl-2,3-dihydro-1 H-innidazo[1 ,2-a]pyrinnidin-5-one - (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-lsopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one - (S)-9-(5-tert-Butyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1 R,5S)-8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl- [1 ,2,4]oxadiazol-5-ylnnethyl)-2-tnfluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-lsoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-lsopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1 -ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1 -(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-trifluoronnethyl-2,3-dihydro-1 H-imidazo[1 ,2-a]pyrinnidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(5-Cyclopropyl-[1 ,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-isopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Cyclopropyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-tert-Butyl-[1 ,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-tnfluoromethyl-[1 ,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-[2-(1 -Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrimidin-1 -yl]acetyl}pyrrolidine-1 -carboxylic acid tert-butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pyrinnidin-1 -yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1 ,2-a]pyrimidin-1 -yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1 ,2,4]triazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofuran-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1 ,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1 ]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrinnido[1 ,2-a]pynnnidin-1 -yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1 ,2,4]oxadiazol-5-ylrinethyl)-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- 9-lsoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pynnnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorpholin-4-yl)-pyndin-4-yl]-2-oxoethyl}-8-tnfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one, isomer

2 of undetermined configuration Z or E

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydropyran-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8^ trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1 -azaspiro[3.3]hept-1 -yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropynmido[1 ,2-a]pyrim 4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1 ,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-9-(2-lsoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoronnethyl-6,7,8,9-tetrahydropynnnido[1 ,2-a]pyrinnidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrinnido[1 ,2-a]pyrinnidin-4-one, diastereoisomer 1 of undeternnined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylnnorpholin-4-yl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-nnethylnnorpholin-4-yl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 1 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-nnethylnnorpholin-4-yl)-8-thfluoromethyl-6,7,8,9-tetrahydropyhmido[1 ,2-a]pyrimidin-4-one,

diastereoisonner 2 of undeternnined absolute configuration on the asynnnnetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-thfluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyhmidin-4-one - (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrinnidin-4-one,

diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin-4-one,

diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1 ,2-a]pyrimidin- 4-one

and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

7) Process for preparing the products of formula (I) as defined in any one of the other claims, according to scheme 2 as defined hereinafter:

Scheme 2:

in which the substituents n, p, q, PG, R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 , R12 and alkyl have the meanings indicated for the products of formula (I) in any one of Claims 1 to 5.

8) As medicaments, the products of formula (I) as defined in any one of Claims 1 to 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

9) As medicaments, the products of formula (I) as defined in Claim 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

10) Pharmaceutical compositions containing, as active ingredient, at least one of the products of formula (I) as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier.

1 1 ) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment or prevention of a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, "mesangial" cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.

12) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers.

13) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of solid or liquid tumours.

14) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers resistant to cytotoxic agents.

15) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

16) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy.

17) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy alone or in combination.

18) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease.

19) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of X-linked myotubular myopathies and Charcot-Marie-Tooth disease.

20) As novel industrial products, the starting products or synthesis

intermediates as defined in Claim 7 as follows:

- of formulae A, B, G and N:

A B a

in which n = 1 , one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and PG is a protective group for amine;

- of formulae E, F, I and J:

in which q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5;

- of formulae P and H:

in which the substituents n, p, q, PG, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1 1 and R12 have the definitions indicated in any one of Claims 1 to 5;

- of formula Q:

in which either q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5, or R1 is -(CH2)m-Ra with Ra being -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy, and the substituents p, q, R2, R3 and R4 have the definitions indicated in any one of Claims 1 to 5.